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Abbreviations: AR, adenosine receptor; BAIB, bis-acetoxyiodobenzene; cAMP, adenosine 3,5-cyclic phosphate; 
CDI, carbonyldiimidazole; Cl-IB-MECA = 2-chloro-N6-(3-iodobenzyl)-5-N-methylcarboxamidoadenosine; 
CHO, Chinese hamster ovary; DMF, N,N-dimethylformamide; DMEM, Dulbecco’s modified Eagle’s medium; 
EDTA, ethylenediaminetetraacetic acid; GPCR, G protein-coupled receptor; HEK, human embryonic kidney; I-AB-
MECA, N6-(4-amino-3-iodobenzyl)adenosine-5-N-methyl-uronamide; NECA, 5′-N-ethylcarboxamidoadenosine; 
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HRMS, high resolution mass spectroscopy; NMR, 
nuclear magnetic resonance; R-PIA, N6-R-phenylisopropyladenosine; TBDMS, tert-butyldimethylsilyl; TCA, 
trichloroacetic acid; TEMPO, (2,2,6,6-tetramethylpyperidin-1yl)-oxyl; THF, tetrahydrofuran; TLC, thin layer 
chromatography; TM, transmembrane helical domain.  
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ABSTRACT 
Adenosine receptors (ARs) trigger signal transduction pathways inside the cell when activated by 
extracellular adenosine. Selective modulation of the A3AR subtype may be beneficial in 
controlling diseases such as colorectal cancer and rheumatoid arthritis. Here, we report the 
synthesis and evaluation of β-D-apio-D-furano- and -D-apio-L-furanoadenosines and derivatives 
thereof. Introduction of a 2-methoxy-5-chlorobenzyl group at N6 of β-D-apio-D-furanoadenosine 
afforded an A3AR antagonist (10c, Ki = 0.98 µM), while a similar modification of an α-D-apio-L-
furanoadenosine gave rise to a partial agonist (11c, Ki = 3.07 µM). The structural basis for this 
difference was examined by docking to an A3AR model; the antagonist lacked a crucial 
interaction with Thr94.  
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INTRODUCTION 
Transmembrane receptors coupled to G-proteins (heterotrimeric guanine nucleotide binding 
proteins) constitute a large receptor family, referred to as G protein-coupled receptors (GPCRs) 
or seven-transmembrane domain (7TM) receptors. Triggered by messenger molecules or signals 
outside the cell, GPCRs activate different signal transduction pathways inside the cell and, 
ultimately, cellular responses. The extracellular messengers range from photons to biogenic 
amines and other neurotransmitters to proteins. GPCRs are ubiquitous and involved in processes 
varying from directed chemotaxis[1] of small organisms (e.g. searching food for survival) to 
triggering apoptosis (programmed cell death) in large animals. They are the targets of almost 50% 
of marketed active pharmaceutical ingredients.[2]  
GPCRs activated by extracellular adenosine are classified as adenosine receptors (ARs), which 
are divided in four different subtypes, i.e. A1, A2A, A2B and A3 ARs.[3,4] The amino acid sequence 
similarity between the human (h) A3AR and hA1, hA2A, hA2B AR is 54 %, 48 % and 44 %, 
respectively.[5] The ARs use different signaling pathways; the A1 AR and A3 AR are 
preferentially coupled to Gi-proteins, and upon activation lead to adenylate cyclase inhibition, 
while the A2A AR and A2B AR are preferentially coupled to Gs-proteins and lead to adenylate 
cyclase activation. In some cells (e.g., mast cells), the A2BAR is dually coupled to Gs and Gq and 
consequently also mobilizes calcium and activates phospholipase C and MAPK. [3,6]  
Besides adenosine (1) itself, which is used clinically for the treatment of supraventricular 
tachycardia and in myocardial perfusion imaging,[7] only one AR-specific agent, the A2AAR 
agonist regedenoson, has so far been approved by the FDA. However, a relatively large group of 
AR ligands is currently under clinical evaluation.[8]  
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With the exception of compound 2, which was reported in the mid-1980s as being inactive at A1 
and A2ARs,[9] and the recently reported carbocyclic analogue 3,[10] a weak A3AR agonist, 4-
hydroxymethyl transposed nucleosides have not been investigated as AR ligands.  
This led us to employ a new and convenient method for the synthesis of apionucleosides from 
1,2-O-isopropylidene-α-L-threose,[11] for the construction of suitably modified 9-(3-C-
hydroxymethyl-β-D-erythrofuranosyl)adenines (aka β-D-apio-D-furanoadenosines) (4-6) and 9-
(3-C-hydroxymethyl--L-threofuranosyl)adenines (aka -D-apio-L-furanoadenosines) (7-9) as 
potential A3AR modulators (Figure 1).  
On the one hand, we envisaged to substitute the N6 position of β-D-apio-D-furanoadenosine 4 
with substituted benzyl groups known to enhance A3AR affinity;[12] on the other hand we 
planned to substitute the well-known ethylcarboxamide moiety in place of the 4-CH2OH 
group.[13] We decided to introduce a benzyl moiety at the N6 position and an N-alkylcarboxamide 
moiety at the 5 position because this combination was shown to be conducive to selectivity at 
the A3AR.  For example, N6-(3-iodobenzyl)-5-N-methylcarboxamidoadenosine and its 2-chloro 
analogue (Cl-IB-MECA) display Ki values at A3AR of ~1 nM and ≥50-fold selectivity for this 
subtype. [14] Subsequently, an N6-(3-chloro-5-methoxybenzyl) substitution was shown to be 
beneficial for A3AR selectivity,[12] and we incorporated this moiety in the current target 
compounds.  
However, synthetic problems in introducing an ethylcarboxamide moiety motivated us to 
introduce a N-methyl or N-ethylcarbamoyloxymethyl group instead. Analogue modifications 
were carried out on α-D-apio-L-furanoadenosine 7. 
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Figure 1. Apio-type nucleosides previously tested for modulation of ARs (1-3) and target 
analogues of the present study (4-15). 
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RESULTS AND DISCUSSION 
Chemistry 
The β-D-apio-D-furanoadenosines 4-6 and the α-D-apio-L-furanoadenosines 7-9 were prepared by 
microwave assisted synthesis as described in ref. [11]. 
 
Scheme 1. Synthesis of N6 substituted apioadenosines. Reagents and conditions: (a) (i) appropriate 
benzyl bromide, DMF, 50 °C, 48 h; (ii) 25% NH4OH, 50 °C, 48 h or 90 °C, 3 h, 20-56% over two steps; 
(b) (i) appropriate benzyl bromide, DMF, rt, 48 h; (ii) 25% NH4OH, 50 °C, 24 h, 8-21% over two steps.  
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The L-threo analogue 7 was used as a model substrate for N6-derivatisation reactions. Treatment 
of 7 with the appropriate benzyl bromide first afforded the N1-benzyl derivative, which was 
isolated in the case of the 3-chlorobenzyl derivative 16 (Scheme 1). Upon prolonged heating 
with ammonia solution, the N1-benzyl intermediates were converted to the desired N6-benzylated 
compounds 11a-11c via Dimroth rearrangement.[14] Although in many cases this method suffered 
from low yields, it allowed gaining fast access to the target molecules. Using similar conditions 
β-D-apio-D-furanoadenosine 4 was benzylated at N6 affording the desired derivatives in low yield 
after purification by RP-HPLC or preparative TLC. In the case of 10c, using excess of the benzyl 
bromide led to degradation of the starting material and afforded bis-(2-methoxy-5-
chlorobenzyl)adenine as observed by HRMS. By limiting the amount of this benzyl bromide to 
one equivalent, 10c could be obtained in 21% yield.  
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Scheme 2. Synthesis of sugar modified α-D-apio-L-furanoadenosines. Reagents and conditions: (a) 
TBDMSCl, imidazole, DMF, 100 °C, 3 days, 80%; (b) 7N NH3 in MeOH, rt, 18 h, 73%; (c) HF.pyridine, 
pyridine, THF, rt or TCA-H2O, THF, rt; (d) TBDMSCl, imidazole, DMF, rt, 18 h, 75-83%; (e) 22, TCA-
H2O, THF, 0°C, 1 h, rt, 1 h, 87%; 23, HF.pyridine, pyridine, THF, 0°C, 1 h, rt, 1 h, 82%; (f) (i) CDI, THF, 
rt, 3h; (ii) EtNH2, rt, 16 h, 55-95%; (g) (i) RuCl3, NaIO4, AcCN-CCl4-H2O, rt, 7 h; (ii) CDI, THF, rt, 3 h; 
(iii) EtNH2, rt, 18 h, 9% over three steps; (h) NH4F, MeOH, 50 °C, 48 h, 70-94%. 
 
